Alkermes plc. (ALKS) stock
ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30208% above fair value
$45.45−1.08 (-2.32%)
Close on Nov 17, 2026Market cap $7.62BP/E 119.6Yield –
Alkermes net income
Net income is the profit left for shareholders after every expense, interest and tax.
Alkermes's net income for the twelve months ending Jun 30, 2026 was $66.12M, down 81.0% year over year. For fiscal 2025 it was $241.66M, down 34.2% from the year before. The highest annual figure on record is $367.07M in fiscal 2024.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $241.66M | -34.2% |
| FY2024 | Dec 31, 2024 | $367.07M | +3.2% |
| FY2023 | Dec 31, 2023 | $355.76M | – |
| FY2022 | Dec 31, 2022 | -$158.27M | – |
| FY2021 | Dec 31, 2021 | -$48.17M | – |
| FY2020 | Dec 31, 2020 | -$110.86M | – |
| FY2019 | Dec 31, 2019 | -$196.62M | – |
| FY2018 | Dec 31, 2018 | -$139.31M | – |
| FY2017 | Dec 31, 2017 | -$157.95M | – |
| FY2016 | Dec 31, 2016 | -$208.44M | – |
| FY2015 | Dec 31, 2015 | -$227.16M | -1009.3% |
| FY2013 | Mar 31, 2013 | $24.98M | – |
| FY2012 | Mar 31, 2012 | -$113.68M | – |
| FY2011 | Mar 31, 2011 | -$45.54M | – |
| FY2010 | Mar 31, 2010 | -$39.63M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $501.00K | -99.4% |
| Q1 FY2026 | Mar 31, 2026 | -$66.48M | -395.9% |
| Q4 FY2025 | Dec 31, 2025 | $49.34M | -66.3% |
| Q3 FY2025 | Sep 30, 2025 | $82.76M | -10.4% |
| Q2 FY2025 | Jun 30, 2025 | $87.10M | -4.7% |
| Q1 FY2025 | Mar 31, 2025 | $22.46M | -39.0% |
| Q4 FY2024 | Dec 31, 2024 | $146.50M | +29.9% |
| Q3 FY2024 | Sep 30, 2024 | $92.38M | +93.4% |
| Q2 FY2024 | Jun 30, 2024 | $91.36M | -61.5% |
| Q1 FY2024 | Mar 31, 2024 | $36.83M | – |
| Q4 FY2023 | Dec 31, 2023 | $112.78M | – |
| Q3 FY2023 | Sep 30, 2023 | $47.76M | – |
| Q2 FY2023 | Jun 30, 2023 | $237.07M | – |
| Q1 FY2023 | Mar 31, 2023 | -$41.85M | – |
| Q4 FY2022 | Dec 31, 2022 | -$28.25M | -3336.4% |
| Q3 FY2022 | Sep 30, 2022 | -$63.97M | – |
| Q2 FY2022 | Jun 30, 2022 | -$30.14M | -1374.8% |
| Q1 FY2022 | Mar 31, 2022 | -$35.90M | – |
| Q4 FY2021 | Dec 31, 2021 | $873.00K | – |
| Q3 FY2021 | Sep 30, 2021 | -$28.99M | – |
| Q2 FY2021 | Jun 30, 2021 | $2.36M | – |
| Q1 FY2021 | Mar 31, 2021 | -$22.42M | – |
| Q4 FY2020 | Dec 31, 2020 | -$42.64M | – |
| Q3 FY2020 | Sep 30, 2020 | -$134.00K | – |
| Q2 FY2020 | Jun 30, 2020 | -$29.43M | – |
| Q1 FY2020 | Mar 31, 2020 | -$38.65M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.35M | – |
| Q3 FY2019 | Sep 30, 2019 | -$52.88M | – |
| Q2 FY2019 | Jun 30, 2019 | -$41.99M | – |
| Q1 FY2019 | Mar 31, 2019 | -$96.40M | – |
| Q4 FY2018 | Dec 31, 2018 | -$9.71M | – |
| Q3 FY2018 | Sep 30, 2018 | -$34.44M | – |
| Q2 FY2018 | Jun 30, 2018 | -$32.65M | – |
| Q1 FY2018 | Mar 31, 2018 | -$62.51M | – |
See a number that looks wrong?